Using a target gene approach, only a few host genetic risk factors for treatment-related myeloid leukemia (t-ML) have been defined. Gene expression microarrays allow for a more genome-wide approach to assess possible genetic risk factors for t-ML. We assessed gene expression profiles (n ¼ 12 625 probe sets) in diagnostic acute lymphoblastic leukemic cells from 228 children treated on protocols that included leukemogenic agents such as etoposide, 13 of whom developed t-ML. Expression of 68 probes, corresponding to 63 genes, was significantly related to risk of t-ML. Hierarchical clustering of these probe sets clustered patients into three groups with 94, 122 and 12 patients, respectively; 12 of the 13 patients who went on to develop t-ML were overrepresented in the latter group (Po0.0001). A permutation test indicated a low likelihood that these probe sets and clusters were obtained by chance (Po0.001). Distinguishing genes included transcription-related oncogenes (v-Myb, Pax-5), cyclins (CCNG1, CCNG2 and CCND1) and histone HIST1H4C. Common transcription factor recognition elements among similarly up-or downregulated genes included several involved in hematopoietic differentiation or leukemogenesis (Maz, PU.1, ARNT). This approach has identified several genes whose expression distinguishes patients at risk of t-ML, and suggests targets for assessing germline predisposition to leukemogenesis.
Background
A major unpredictable complication in the treatment of acute lymphoblastic leukemia (ALL) is treatment-related myeloid leukemia (t-ML), which includes treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), occurring in 1-10% of ALL patients. 1, 2 Characteristics of the ALL subtype do not appear to influence the risk of t-ML. [3] [4] [5] [6] [7] [8] [9] Two major types of t-ML have been reported: the form associated with the use of topoisomerase II inhibitors, 3, 5, 6 with characteristic balanced translocations of the MLL gene, [10] [11] [12] and the form associated with alkylating agents 7, 8 associated with monosomy of chromosome 5 or 7. 4 Although several treatment-related risk factors have been identified that interact with the primary leukemogens, few host factors are known. As survival of cancer therapy increases, the importance of identifying host factors for secondary neoplasms increases.
Because DNA microarrays interrogate multiple (410 000) genes in one experiment, they allow for a 'genome-wide' assessment of genes that may predispose to leukemogenesis. DNA microarray analysis of gene expression has been used to identify distinct expression profiles that are characteristic of different leukemia subtypes. 13, 14 Studies using this method have led to the identification of molecular events in the progression of chronic myeloid leukemia (CML) [15] [16] [17] [18] and to the classification of AML and ALL subtypes. 13, 19 Microarray analysis has also been used in childhood ALL to identify gene expression patterns at diagnosis associated with risk of ALL relapse. 13, 20 Variation in gene expression is likely to partly reflect variation in germline DNA. Gene expression in lymphoid tissue reflects inherited traits in cell lines from large kindreds. 21 That gene expression in ALL blasts differs by germline genetic polymorphisms, 22 and can even predict which patients were likely to eventually develop a therapy-induced brain tumor, 23 is also consistent with the hypothesis that gene expression in ALL cells partially reflects germline characteristics, and not only the acquired genetic signature of the ALL subtype. In an initial analysis, gene expression profiles of diagnostic ALL cells were also predictive of t-ML risk, 13 but these data were analyzed in depth only among the largest molecularly defined ALL subgroup: those with Tel/AML1 translocations at diagnosis. Moreover, the time dependence of t-ML and competing risks for relapse were not considered.
In this study, we used a genome-wide approach to identify genes whose expression discriminated patients with ALL who were predisposed to t-ML, using cumulative incidence and Cox regression models for assessing the relationship between gene expression and time to t-ML. The two models identified 68 common probe sets, corresponding to 63 genes, whose expression in ALL cells differed significantly between patients who did versus those who did not develop t-ML. These results suggest that pretreatment gene expression profiling can provide insights into candidate genes involved as host factors in t-ML development.
Patients, materials and methods

Patients and laboratory tests
Protocols Total XIIIA (1991) (1992) (1993) (1994) and Total XIIIB (1994) (1995) (1996) (1997) (1998) of St Jude Children's Research Hospital were used for the treatment of patients with newly diagnosed ALL. Both protocols included the administration of topoisomerase II inhibitors and alkylating agents. 24, 25 The patient cohort herein consisted of all 267 patients (228 with B-lineage and 39 with T-cell ALL) who were enrolled on the protocols and for whom gene expression data from ALL cells at diagnosis were available. The median length of follow-up was 6.1 years. In all, 14 patients developed t-ML: 13 had B-lineage ALL and one patient had T-cell ALL as the primary malignancy. The types of therapy-related leukemias were AML (n ¼ 10), MDS (n ¼ 3), and CML (n ¼ 1). Herein, we restricted our analysis to those with B-lineage ALL for the primary analysis (228 patients), but an identical analysis for all 267 patients (those with T-or B-lineage ALL), is presented in the Supplementary Information. Bone marrow blasts of ALL patients were cryopreserved on the date of diagnosis. Total RNA was extracted using TriReagent (MRC, Cincinnati, OH, USA). Patients, their parents, or guardians gave informed consent and assent to participate in the study. The protocols and the current analysis of risk factors were approved by the Institutional Review Board of St Jude. RNA was submitted for microarray analysis as described. 13 Labeled cRNA was hybridized to Affymetrix HG-U95Av2 GeneChips, which comprise more than 12 600 probe sets for more than 9600 unique genes. Gene expression was verified by a second method in a subset (see Supplementary Information).
Statistical analysis
Gene expression data were extracted from Affymetrix-generated image files using MicroArray Suites (MAS) version 5.0. with default settings (Raw data available on http://www.stjuderesearch.org/data/ALL1). The MAS 5.0-generated signal of each probe set was transformed by natural-log transformation (log e ).
Statistical analysis was performed using SAS (SAS Inc., Cary, NC, USA), S-plus (Insightful, Seattle, WA, USA), StatXact 5 (Cytel, Cambridge, MA, USA) and R 1.6 (http://www.r-project. org/). For data visualization, principal component analysis (PCA) and hierarchical clustering were performed using Spotfire DecisionSite 7.0 (Spotfire, USA).
All analyses were performed on the entire cohort (n ¼ 267) and the subcohort of B-lineage ALL patients (n ¼ 228).
As development of t-ML depends on the follow-up time, and other competing risks may be present, we performed gene/probe set selection using two types of statistical models that relate gene expression levels with the hazard function for the at-risk time for t-ML.
Cumulative incidence regression model
To discriminate patients at high risk of t-ML from those at low risk, gene selection and gene validation were performed using Fine and Gray's 26 cumulative incidence regression model relating the time at risk of t-ML to gene expression, and allowing other outcomes as competing risks. AML, MDS, and CML were considered to be t-ML events. Death in remission, relapse, and secondary malignancy other than t-ML, were considered as competing events. This time-dependent approach used three variables for each patient and each probe set: the time to event, the outcome phenotype (no event, t-ML, adverse event other than t-ML), and the gene expression in ALL cells before treatment. For each probe set, a cumulative incidence regression model was fitted, with gene (probe set) expression level as the explanatory variable. Probe sets with Pp0.01 were considered as 'statistically significant. ' Cox regression model 27, 28 Although relapse of the primary ALL (or occurrence of other type of failure) does not necessarily remove a patient from the at-risk set for t-ML, that risk can be so altered by that failure (or its attendant change in therapy) that it is improbable to observe a t-ML in such patients. In our particular study, no patient who developed t-ML experienced a competing adverse event before the t-ML. For this reason, we have also conducted a Cox regression model analysis, in which we censored patients with relapse (or other failures) at the times of such events, and used survival models, instead of cumulative incidence models, for purposes of gene/probe set selection. Probe sets with Pp0.01 were considered as 'statistically significant. ' 
Cluster analysis
Hierarchical clustering (Ward's minimum-variance method) was applied to cluster the patients into three groups, using the expression of probe sets selected by the above methods as features. As three major outcomes were present (no event, t-ML, adverse events other then t-ML), the cluster tree was cut at the level that defined k ¼ 3 clusters. The cumulative incidence of t-ML among the three clusters was compared using Gray's test, using adverse events other than t-ML as competing risks. 29 
Permutation test
To assess the probability that the discriminating probe sets could have been selected by chance, a permutation test was performed separately for each group of selected probe sets (using the methods described above). For these permutations, outcome was treated as a time-dependent event, allowing us to combine features of a 'classification accuracy' with a cumulative incidence comparison approach. In each of 1000 permutations, the paired time-to-t-ML development and outcome event were randomly reassigned to each patient, and gene selection was performed by applying either the cumulative incidence regression or the Cox regression model to the permuted data. The a value of 0.01 was the significance threshold, the same as used on the original data. The permuted samples were then clustered into three groups using the hierarchical clustering algorithm, and the cumulative incidence of t-ML among the three clusters was compared using Gray's test. A permutation result was considered significant only if: (1) the number of probe sets selected at a ¼ 0.01 level was greater than or equal to 1; (2) the cluster with the highest percentage of t-ML events contained at least k t-ML cases, with k the number of t-ML cases observed in the cluster generated from the original data and containing the highest number of t-ML cases; and (3) the test statistic was greater than or equal to the w 2 statistic value from the observed data. The second criterion was included to avoid the possibility of a permutation resulting in a very small cluster consisting entirely of a few t-ML events that would result in undue 'significance' to a permutation.
Genotyping
DNA was extracted from whole blood collected after achieving complete remission from the subset of 153 patients treated on protocol Total 13B. 30 We designed three PCR reactions to amplify the 3 kb region of chromosome 6 bracketing the HIST1H4C gene and its promoter using three pairs of primers: forward GTTTGTGGAGGGTAGTTCTGGACA and reverse TAC TTGATTAAGGTCATTACAAAAT, forward TAGCTAAGTCTCTA GTTATAAGGTC and reverse GGACCTGATTGAAAACAACATG AGT, and forward TAAATCCCTTGACCTATAAATCTGA and reverse CTTTATTAGCGCTTACCTCTCTATG. We also extracted DNA from the subset of 24 anonymized individuals that Table 1 Candidate genes associated with t-ML development after ALL treatment among 228 B-lineage patients We found 68 probes in common using a cumulative incidence regression model and a Cox regression model to define probes significantly associated with time to t-ML development (a ¼ 0.01). Probeset: probe set name. Description: Gene annotations for the human U95A chip, available at http://hcapps2.web.stjude.org/hcnetdat/affy/u95Av2.php Relative expression of the probe set in those who did develop t-ML compared to those who did not. P-value for the w 2 test.
represent ethnic diversity in one of the DNA Polymorphism Discovery Resource panels (http://ccr.coriell.org/nigms/Coriell, NJ, USA). 31 The genotyping and expression data are available on www.pharmgkb.org.
Promoter analysis
We analyzed 3000 bp of upstream regulatory sequences for each discriminating gene, focusing on the 68 probe sets which were in common for the Cox regression and the cumulative incidence models. Genes were divided into two groups, based on under-or overexpression. The sequences were retrieved by the method described elsewhere 32 and further confirmed by comparison to the UCSC promoter sequences at the UCSC Genome Browser (http://genome.ucsc.edu). Probe sets (both down-and upregulated) that did not contain a valid transcriptional start site or ill-defined exon boundaries were not included in the analysis. The retrieved sequences were first masked for repeats using RepeatMasker (http://www.repeatmasker.org/) and analyzed using CLOVER. 33 Briefly, this program identifies 5 0 DNA sequences that are shared by genes by comparing them against a precompiled library of sequence motifs, and assesses which of the motifs are statistically overrepresented in the target sequence relative to a baseline file of 18 406 known human upstream sequences (5000 bp) from the UCSC Genome database (http://genome.ucsc.edu). DNA matrices (n ¼ 762) as defined in the TRANSFAC s database (Release 9.2 & Biobase GmbH) were used in the analysis. Motifs with P-values o0.01 (positive raw score) were considered as overrepresented.
Results
Of the 228 patients with B-lineage ALL, 13 developed t-ML, and 34 patients developed competing events, that is, relapse, death, or other types of treatment failure. At the time of the analysis, 181 patients remained in complete remission.
Statistical analysis
Using Fine and Gray's cumulative incidence regression model, we identified 256 probe sets significantly associated with time to t-ML development (a ¼ 0.01; Supplementary Table S1 and Supplementary Figure S2) . Using a Cox regression model, we identified 83 probe sets significantly associated with t-ML development (a ¼ 0.01; Supplementary Table S2 and Supplementary Figure S4 ), 68 (82%) of which were in common with the probe sets identified with the cumulative incidence regression model (Table 1) . We focused on these 68 probe sets for further analysis. PCA indicated that the expression of these 68 probe sets differentiated the patients who went on to develop t-ML from those who remained in remission or relapsed (Figure 1 ). We classified the 228 patients into three groups based on hierarchical clustering using these 68 probe sets: 12 of the 13 t-ML patients were classified into cluster 3, with high association between clustering and type of event (exact w 2 test, Po0.0001, Table 2 ); the 7-year cumulative incidence of t-ML was higher in cluster 3 (10078.3%) than in cluster 2 (0.870.8%) and cluster 1 (0%) (Gray's test, Po0.0001, Figure 2 ). Permutation, indicating the likelihood of obtaining probe sets that distinguished the group with t-ML by chance, gave a P-value of 0.015 (k ¼ 12).
No association was observed between genetic subtype of ALL (i.e. hyperdiploid, Tel/AML1, BCR/ABL, MLL etc) and patient clusters defined by gene expression and hierarchical clustering (Monte Carlo exact w 2 test, P ¼ 0.53). In comparison with children who did not develop t-ML, children who developed t-ML showed altered expression of some key kinases (MAP2K1 and PGK1), of components critical for the S-phase cell cycle progression (CCNG1, CCNG2, and CCND1), and of oncogenes such as MYB and Pim-2, which were downregulated. Genes belonging to the pre-mRNA and alternative mRNA splicing, SRP46 and DDX17, were underexpressed. CDK8 and the largest subunit of the RNA polymerase II, both components of the same holoenzyme complex involved in the regulation of transcription, were downregulated. Gene expression was verified by real-time reverse transcriptionpolymerase chain reaction in a subset of patient samples for Figure 1 Tridimensional scatter plot of the three principal components from an analysis of the 68 common probe sets whose expression distinguished patients who developed t-ML (n ¼ 13) from those who did not develop t-ML (n ¼ 215). Each sphere represents a patient, different colors represent the four types of outcome events: green, event-free survival (n ¼ 181); red, t-ML (n ¼ 13); black, other secondary malignancies (n ¼ 1); blue, other adverse events (n ¼ 33). Table 2 Using hierarchical clustering of n ¼ 68 probes (found in common with the cumulative incidence and Cox regression models) whose expression distinguished t-ML among the 228 B-lineage patients, three clusters were defined
Cluster
Reason for censoring
No event t-ML Death or event other than second malignancy
Other second malignancy Total   1  80  0  14  0  94  2  101  1  19  1  122  3  0  12  0  0  12  Total  181  13  33  1  228 The distributions of outcomes for patients are indicated, with 12 of the 13 cases of t-ML concentrated in cluster 3 (w 2 ¼ 229.6, Po0.0001). The permutation P-value was 0.015 (k ¼ 12).
four genes (POLIIa, Myb, SLC25A6, HIST1H4C) that discriminated patients who developed t-ML (Supplementary Figure S1) .
Genotyping
As proof of principle that underlying genomic variation may affect gene expression, we compared HIST1H4C expression by germline HIST1H4C genotypes (Supplementary Table S3 ). HIST1H4C expression was significantly higher in patients who developed t-ML compared to children who did not (Table 1) . HIST1H4C expression level differed significantly (P ¼ 0.032) by genotype at an A4G polymorphism (rs1543680) located 999 bp 5 0 of the transcription starting site of the gene (Figure 3) , with highest expression in those patients with the A/A, intermediate in those with A/G, and lowest in those with the G/G genotype. Interestingly, this polymorphism was located in a putative binding site sequence for the transcription factor PU.1. However, there was no difference in the allele frequencies of the minor allele of rs1543680 between patients who developed t-ML (frequency of A allele ¼ 0.14) and patients who did not develop t-ML (frequency of A allele ¼ 0.15) (P ¼ 1), nor between the entire cohort of ALL patients (frequency ¼ 0.15) and a control group consisting of the 24 ethnically diverse individuals who constitute a subgroup of the DNA Polymorphism Discovery Resource (n ¼ 24) (frequency ¼ 0.17) (P ¼ 0.68).
Promoter analysis
Using the criteria outlined in the Patients, materials and methods, 10 and nine transcription factor-binding sites were overrepresented among genes that were overexpressed and underexpressed, respectively, in the cases who developed t-ML relative to the controls who did not (Supplementary Table S4a and S4b). The recognition sequence for PU.1 (coded for by the Sfpi1 gene, an Ets family transcription factor) was among the 10 transcription factor-binding sites, corresponding to eight transcription factors (Figure 4) , whose recognition sequence motifs were overrepresented (Supplementary Table S4a) among genes whose overexpression distinguished the t-ML cases, along with MAZ (Myc associated zinc finger), STAT5A (signal transducer and activator of transcription 5A) and STAT6 (signal transducer and activator of transcription 6). Nine binding sites, corresponding to seven transcription factors (Figure 4) , were overrepresented among genes whose expression was low in the cases who developed t-ML, including transcription factor-binding sites for ARNT (aryl hydrocarbon receptor nuclear translocator), MZF-1 (myeloid zinc finger 1), AP-2, and NF-kB (Supplementary Table S4b) .
Discussion
In the current study, we identified a set of genes whose expression differentiated children with ALL who did versus did not develop therapy-related leukemia, with 12 of the 13 patients who ultimately developed t-ML segregating into the same major gene expression cluster. We and others have previously extensively studied the treatment-related, and to some extent, host-related risk factors for the devastating complication of t-ML among children with ALL. 34, 35 Treatment-related factors include the use of topoisomerase II-targeted drugs, along with co-leukemogens such as thiopurines, irradiation, and G-CSF use. 24 The key initiating event is likely related to the double-strand DNA breaks stabilized by topoisomerase II agents, which can lead to recombinogenic formation of leukemogenic chimeric gene fusions. 36 The misrepair of etoposide-stabilized doublestrand DNA breaks is intrinsic to the generation of gene fusions that can cause t-ML. 37 However, the fact that t-ML develops in only a subset of patients exposed to leukemogenic treatment strongly suggests the presence of host-related genetic risk factors Figure 2 Cumulative incidence of t-ML in the three gene expression groups defined by hierarchical clustering of the 68 selected probe sets. The cumulative incidence was significantly higher in cluster 3 compared to other two clusters at year 7 (w 2 ¼ 202.9, Po0.0001). The permutation Pvalue was 0.015 (k ¼ 12). that favor recombinogenesis and development of t-ML, rather than apoptosis due to double-strand DNA breaks.
Based on the complexity of the leukemogenic process, there is an inordinately large number of candidate genes that could be linked to the risk of t-ML. Using a forward-genetic, phenotypeto-genotype approach, only modestly penetrant genetic predisposing factors have been identified. A reverse genetic, genotypeto-phenotype approach, may be useful to focus in on candidate genes for this drug-induced phenotype. Microarrays for gene expression provide one such genome-wide tool.
The differentially expressed genes in children who developed t-ML included those whose cellular functions can be directly linked to the process of double-strand DNA break repair or misrepair, although none have been previously studied in t-ML. Among these were genes linked to regulation of transcription and DNA recombination (v-Myb, Pax-5, POLR2A and CDK8), cell cycle progression (CCNG1, CCNG2, CCND1, CDK8), apoptosis (Pim-2, ANT3), and a histone protein (HIST1H4C).
MYB is a transcription factor expressed in immature hematopoietic cells that regulates proliferation and differentiation. 38 MYB and PAX5 39 can cooperate to activate RAG-2 expression, 40 with RAG-2 introducing double-strand DNA breaks in V(D)J recombination. [41] [42] [43] [44] Inappropriate triggering of V(D)J recombination can be caused by etoposide, 45, 46 the key leukemogenic component of the ALL therapy associated with t-ML. Thus, altered expression of PAX5 and MYB could affect one of the key DNA recombination processes perturbed by etoposide.
Cell cycle arrest is an alternative to apoptosis as a response to DNA damage, and could facilitate the formation of chimeric fusions during the period of stabilized DNA breaks. Children with t-ML had altered expression of genes involved in cell cycle regulation, CCNG1, CCNG2, CDK8 and CCND1. Cyclin G1 (CCNG1) is a target of p53 and is induced in the cell cycle arrest response to DNA damage. 47, 48 Altered expression of cyclins could prolong G1 and be one of the reasons that cells fail to respond to DNA-damage stimuli that would otherwise promote exit from the cell cycle. The proliferation of cells carrying misrepaired DNA could lead to leukemic transformation.
Histones regulate accessibility of DNA to DNA-modifying and DNA-interacting enzymes. 49 The double-strand DNA breakage and religation required for faithful DNA recombination is affected by histone status. [49] [50] [51] Histone H4 (HIST1H4C) expression was higher in children who developed t-ML, and was the only distinguishing gene that was also found in the prior analysis of the subset of these children whose ALL blasts carried the Tel-AML1 translocation. 13 We also found that HIST1H4C was upregulated in human lymphoid CEM cells after treatment with etoposide (data not shown). As proof of principle, we demonstrated that a germline polymorphism in the 5 0 region of the HIST1H4C gene explained some of the variability in its expression (Figure 3) , even though the allele frequencies of this SNP did not differ in the two groups of patients. Interestingly, this polymorphism was located in a binding site for the transcription factor PU.1. In addition, PU.1-binding sites were Figure 4 Network connection for t-ML genes and transcription factors. The CLOVER analysis of 3000 bp of upstream regulatory sequences for each of the 68 discriminating genes revealed 53 with overrepresented transcription factor-binding sites relative to other genes. All transcription factors whose binding sites were overrepresented among differentiating genes are depicted in the outer circle; all the genes (n ¼ 53) with overrepresented transcription factor-binding site sequences in their promoter are represented in the inner circle, with lines connecting each gene to the corresponding transcription factor: black nodes are overexpressed and red are underexpressed genes in patients who developed t-ML.
significantly overrepresented (Figure 4 ) in the upstream regulatory regions of genes whose expression discriminated patients who developed t-ML. PU.1 expression is strictly regulated in hematopoietic cells, it determines the differentiation of myeloid from lymphoid lineages, 52 and a decrease in PU.1 can cause AML in mouse models. 53, 54 Thus, these findings suggest additional targets that could be important in the genesis of t-ML.
Other transcription factor-binding sites that were overrepresented in the genes whose expression differentiated the cases who developed t-ML included sites targeted by MAZ, ARNT, STAT6, NF-kB and MZF1 (Figure 4) . Several of these transcription factors have been linked to leukemogenesis. 55 Thus, it is possible that a common upstream regulatory pathway affects the expression or activity of a transcription factor, and that through its action on a common binding element, this factor could affect the expression of multiple downstream gene targets that are themselves involved in or markers of leukemogenesis.
The genes identified by the 68 distinguishing probe sets were compared to other data sets possibly related to the mechanisms of leukemogenesis relevant for t-ML. There were no genes in common with those that distinguished B-precursor ALL carrying an MLL translocation compared to B-precursor ALL lacking this translocation, 56 and no genes in common with the expression profiles of de novo acute leukemias. 57 Two genes (HIST1H4C and HLA-DQB1) were in common with those predictive of t-ML in the TEL-AML1 subgroup in our preliminary analysis, 13 and three genes (Po0.05, NR2C1, MPST, SRP46) were in common with those that distinguish resistance to etoposide among the NCI60 cell lines (http://discover.nci.nih.gov). We treated the human ALL cell line CEM with etoposide (data not shown), and found two genes (HIST1H4C, SFRS6) whose expression at least doubled over 8 h that were in common with the 68 distinguishing probe sets.
In an analysis such as this, the phenotype (t-ML) is relatively rare but critically important, in that it is nearly universally fatal. Thus, it is important to establish promising leads for genetic risk factors. We found 68 genetic probe sets that distinguished the t-ML cases, and it is likely that this group includes some falsepositive findings and could miss some other genetic factors. Although the number of patients available for study is too small for testing the robustness of the gene set by establishing training and test sets, we estimated that our false discovery rate was only 1.5%, an acceptable rate given the substantial need to identify risk factors for therapy-induced leukemias.
Tools for genome-wide interrogations to identify possible genetic risk factors for important phenotypes remain in the early stages of development. Particularly for phenotypes (such as second cancers) induced by potentially genotoxic therapy, linkage analysis through family studies is not an option. Microarray gene expression analysis is one tool that may feasibly be used to survey the genome. Recently, gene expression patterns in diagnostic ALL cells were used as a genome-wide interrogative tool to identify possible genetic risk factors for irradiation-induced brain tumors, 58 and to identify expression patterns linked to germline genetic variation. 21, 22 Our current findings using genome-wide expression analysis provide important new insights into potential genomic determinants of susceptibility to treatment-induced second cancers.
